Why Senti Biosciences, Inc.’s (SNTI) Stock Is Up 11.51%
As of Tuesday, December 09, Senti Biosciences, Inc.’s SNTI share price has surged by 11.51%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Senti Biosciences Holdings, Inc. (SNTI)
Senti Biosciences Holdings, Inc. SNTI
$0.34
-0.02
-5.52%
July 31, 2026 4:00:00 PM
EST
Volume: 148,855
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company’s lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Senti Biosciences, Inc.’s (SNTI) Stock Is Down 17.99%
As of Tuesday, December 09, Senti Biosciences, Inc.’s SNTI share price has dipped by 17.99%, which has investors questioning if this is right time to buy.Tudor Pop
Why Senti Biosciences, Inc.’s (SNTI) Stock Is Up 6.10%
As of Monday, December 08, Senti Biosciences, Inc.’s SNTI share price has surged by 6.10%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Senti Biosciences, Inc.’s (SNTI) Stock Is Down 6.08%
As of Friday, December 05, Senti Biosciences, Inc.’s SNTI share price has dipped by 6.08%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Senti Biosciences, Inc.’s (SNTI) Stock Is Down 5.61%
As of Monday, December 01, Senti Biosciences, Inc.’s SNTI share price has dipped by 5.61%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | SNTI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $11.2 | $251.9 | 7% |
|
| Shares Out (Mil) | 31.0 | 50.8 | 38% |
|
| Institutional Ownership | 83.0% | 92.0% | 51% |
|
| Float (Mil) | 12.3 | 40.5 | 22% |
|
| Beta | 2.05 | 0.95 | 93% |
|
| Avg Daily Volume (000s) | 276 | 447 | 50% |
|
| Price Change (52-week) |
(80.0%) | 54.2% | 7% |
|
| Growth | SNTI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | (25.3%) | (9.8%) | 16% |
|
| EPS (5yr) | 28.2% | 16.3% | 79 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.8%) | (15.6%) | 46% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 2 | |
| Current EPS | ($0.317) | ($1.157) | ($0.950) | |
| Month Ago EPS | ($0.317) | ($1.157) | ($0.950) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.277) | ($1.093) | ($0.895) | |
| Year/Year Chg | 133.1% | (57.7%) | (57.4%) | |
| Financials | SNTI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($52) | ($43) | 16% |
|
| EPS (TTM) | ($1.859) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($37) | ($30) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($25) | $3 | 25% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $5 | 30% |
|
| Enterprise Value (Q1) (Mil) | $40 | $182 | 15% |
|
| Valuation | SNTI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.50 | 2.60 | 76% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | SNTI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (85.2%) | (49.7%) | 7% |
|
| ROE | (255.0%) | (55.4%) | 3% |
|
| Liabilities to Assets | 93.3% | 30.3% | 91% |
|
| F-Score | 2 | 3 | 7% |
|
Senti Biosciences Holdings, Inc. did not pass any screens on 7/30/2026.
